Phase I Trial to Test New Anti-HER2 Pill

Featured Clinical Trials
July 23, 2015
By: 
Nicole Katze, MA, Editor and Manager, Content Development
Reviewed By: 
Stefan Glück, MD, PhD

Study will assess safety and benefit of giving an experimentalinfo-icon medicineinfo-icon with T-DM1 to treat metastaticinfo-icon, HER2-positive breast cancer

Researchers seek 48 women for a small, phase IB study of ONT-380, a new anti-HER2 medicine that can be taken by mouth. The pill will be given along with the standard amount of T-DM1, by veininfo-icon.

About Phase I Clinicalinfo-icon Trials

During phase I trials, a medicine is tested for the first time in humans, following several years of lab research and testing of the medicine in animals. The FDAinfo-icon must agree a treatment is reasonably safe before phase I trials can begin enrolling participants.  

Over the course of the study, the trial team closely  watches participants to find out how much of the medicine to give, in what way it is best given (by mouth, by vein, etc.), and whether it is safe to use. Safety is measured by watching for side effects that impact health or quality of lifeinfo-icon.

Sometimes, phase I trials combine a new medicine with one in standard use. This kind of trial is called a phase IB trial.

Background

HER2-positive breast cancer grows when there are too many HER2 proteins present on breast cells. These extra proteins cause uncontrolled growth of the cells, or cancer. To treat the disease, doctors use anti-HER2 medicines that target the proteininfo-icon and stop it from helping cancer cells divide and spread. T-DM1 (Kadcyla) and trastuzumabinfo-icon (Herceptininfo-icon) are two common examples of anti-HER2 therapies.

ONT-380 is a substance that also works to stop the HER2 protein from helping cancer grow. Past trials studied ONT-380 used alone to treat metastatic breast cancer, but doctors believe combining it with another anti-HER2 therapyinfo-icon may work better.

To find out, the trial team is assessing the combination of ONT-380 with T-DM1.

Goals

The researchers hope to find out

  • what doseinfo-icon of ONT-380 works best, and most safely, with T-DM1
  • how many tumors shrink or disappear with treatment, called tumorinfo-icon response
  • the combination’s impact on progression-free survivalinfo-icon, the time from the start of treatment until the disease grows or spreads, or until death from any cause

Structure

  • Group 1 will take 300mgs of ONT-380 by mouth twice a day for a 21-day cycle, with T-DM1 given by vein every 21 days

If this group does not have disease growth and the combination is safe, then

  • group 2 will take 450mgs of ONT-380 by mouth twice a day for a 21 day cycle, with T-DM1 given by vein every 21 days

If this second group does not have disease growth and the combination is safe, then

  • group 3 will take 600mgs of ONT-380 by mouth twice a day for a 21 day cycle, with T-DM1 given by vein every 21 days

Participants will be followed up every 6 weeks for the first six cycles, and every 9 weeks starting with the seventh cycle.

Imaginginfo-icon scans will be taken every two cycles for the first six cycles, and then every three cycles after, to monitor how much the tumor grows or shrinks.

Eligibility

You may be eligible to take part in this trial if you

  • are a woman at least 18 years of age with metastatic, HER2-positive breast cancer
  • have been treated with a taxaneinfo-icon-based chemotherapyinfo-icon and trastuzumab in the past
  • are not currently being treated with chemotherapy or radiation therapyinfo-icon
  • meet certain blood count requirements

You may not be eligible if you

  • have untreated brain metastases
  • have heart disease
  • have hepatitis B or C
  • are taking medicines that might interact with ONT-380

For more information or to find out if you are eligible, talk with your doctor about trial NCT01983501 on ClinicalTrials.gov.

Locations

This study is being held in Aurora, Colo., Nashville, Tenn., and Boston. For a full list of locations and contact information, visit ClinicalTrials.gov.

 

You must have Javascript enabled to use this form.

More In Targeted Therapy

Additional Related Topics 
HER2-Positive
Metastatic
Clinical Trials